The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).
 
Ignacio Garrido-Laguna
Consulting or Advisory Role - Abbvie; Jazz Pharmaceuticals; Kanaph Therapeutics; OncXerna Therapeutics; SOTIO
Research Funding - 280 BIO (Inst); ABM (Inst); Bayer (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); EcoR1 Capital; GlaxoSmithKline (Inst); Guidepoint Inc; Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tango Therapeutics (Inst); Tolero Pharmaceuticals (Inst); Yingli Pharma (Inst)
 
Brian Wolpin
Consulting or Advisory Role - Agenus; EcoR1 Capital; GRAIL; Ipsen; Mirati Therapeutics; Revolution Medicines; Third Rock Ventures
Research Funding - AstraZeneca (Inst); Harbinger Health (Inst); Lilly (Inst); Novartis (Inst); Revolution Medicines (Inst)
 
Wungki Park
Honoraria - American Physician Institute; Curio Science; IntegrityCE
Consulting or Advisory Role - Astellas Pharma; Cerner Enviza; EXACT Therapeutics; Innovent Biologics; Regeneron
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Break Through Cancer (Inst); Merck (Inst); Miracogen (Inst); NIH (Inst); NIH (Inst); Parker Institute for Cancer Immunotherapy (Inst); Revolution Medicines (Inst); The Society of Memorial Sloan Kettering (Inst)
 
Nilofer Azad
Stock and Other Ownership Interests - Haystack Oncology; Irazu; Tempus
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Taiho Pharmaceutical; Tempus
Speakers' Bureau - AstraZeneca
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Revolution Medicines (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Alexander Starodub
No Relationships to Disclose
 
David Sommerhalder
Employment - Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology/US Oncology
Honoraria - Syneos Health
Consulting or Advisory Role - Revolution Medicines
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Ascentage Pharma (Inst); Biomea Fusion (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immuneering (Inst); Kura Oncology (Inst); MediLink (Inst); Mirati Therapeutics (Inst); Monopteros Therapeutics (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Revolution Medicines (Inst); Symphogen (Inst); Teon Therapeutics (Inst); Vividion Therapeutics (Inst); ZielBio (Inst)
 
Salman Punekar
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); NCI (Inst); Neogene Therapeutics (Inst); Prelude Therapeutics (Inst); Revolution Medicines (Inst); Simcere (Inst); Tango Therapeutics (Inst); VITRAC Therapeutics (Inst)
 
Benjamin Herzberg
Honoraria - Boxer Capital; Eisai; IDEOlogy Health; OncLive/MJH Life Sciences
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi-Sankyo; IDEAYA Biosciences; Johnson and Johnson; Lilly
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; IDEAYA Biosciences (Inst); Lilly (Inst); Monte Rosa Therapeutics (Inst); Nested Therapeutics (Inst); Prelude Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - DAVA Oncology
 
Minal Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Takeda (Inst)
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Jennifer Valerin
Consulting or Advisory Role - AstraZeneca; Myriad Genetics
Speakers' Bureau - AstraZeneca
 
Joel Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals; Trumvira
Consulting or Advisory Role - Astellas Pharma; BeiGene; Bristol-Myers Squibb/Medarex; Galvanize Therapeutics; IgM Biosciences; MBQ Pharma; Taiho Pharmaceutical
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Amgen (Inst); Bold Therapeutics (Inst); Camurus (Inst); Cardiff Oncology (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Janssen Oncology (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neogene Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Regeneron (Inst); Revolution Medicines (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Xilio Therapeutics (Inst)
 
Rashmi Vora
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Aparna Hegde
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
Travel, Accommodations, Expenses - Revolution Medicines; Revolution Medicines
(OPTIONAL) Uncompensated Relationships - Genentech; Sanofi
 
Clay Gustafson
Employment - Revolution Medicines
 
Lin Tao
Employment - revolution medicines inc
Stock and Other Ownership Interests - revolution medicines inc
 
Sumit Kar
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Kevin Lin
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
Travel, Accommodations, Expenses - Revolution Medicines
 
David Hong
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - crossbridge Bio; MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Amgen; Bayer; BeiGene; Bristol Myers Squibb Company; Janssen; Mirati Therapeutics; Sanofi and Genzyme US Companies
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Deciphera Pharmaceuticals Inc. (Inst); Genentech (Inst); Incyte (Inst); Merck Sharp & Dohme LLC (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; CLCC; Genmab; Society for Immunotherapy of Cancer; Telperian